Topical Antibiotics in Dermatology

Archives of Dermatology

Volumn 124, Issue 11, 1988, Pages 1691-1700

  Hirschmann, J V ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; BENZOYL PEROXIDE; CLINDAMYCIN; ERYTHROMYCIN; HEXACHLOROPHENE; METRONIDAZOLE; NEOMYCIN; PSEUDOMONIC ACID; RETINOIC ACID; TETRACYCLINE;

ACNE; DRUG EFFICACY; DRUG RESISTANCE; HUMAN; IMPETIGO; PRIORITY JOURNAL; REVIEW; ROSACEA; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; TOPICAL DRUG ADMINISTRATION;

ACNE ROSACEA; ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ANTIBIOTICS; CATHETERS, INDWELLING; DRUG RESISTANCE, MICROBIAL; ECZEMA; HUMAN; IMPETIGO; PYODERMA; SKIN DISEASES; SOAPS; SURGICAL WOUND INFECTION;

EID: 0023716887     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1988.01670110051011     Document Type: Article

References (121)

1. Anderson V (ed): Over-the-counter topical antibiotic products: Data on safety and efficacy. Int J Dermatol 1976;15(suppl):1–118.
2. MacDonald RM, Beck M: Neomycin: A review with particular reference to dermatologic usage. Clin Exp Dermatol 1983;8:249–258.
3. Katz BE, Fisher AA: Bacitracin: A unique topical antibiotic sensitizer. J Am Acad Dermatol 1987;17:1016–1024.
4. Lorenzetti OJ, Wernet TC, Breslauer CM: Antimicrobial properties of gentamicin on the skin. Int J Dermatol 1984;23:547–549.
5. Sutherland R, Boon RJ, Griffin KE, et al: Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 1985;27:495–498.
6. Hellgren L, Vincent J: Topical erythromycin for acne vulgaris. Dermatologica 1980;161:409–414.
7. Rivkin L, Rapaport M: Clinical evaluation of a new erythromycin solution for acne vulgaris. Cutis 1980;25:552–555.
8. Burke B, Eady EA, Cunliffe WJ: Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. Br J Dermatol 1983;108:199–204.
9. Dobson RL, Belknap BS: Topical erythromycin solution in acne. Results of a multicenter trial. J Am Acad Dermatol 1980; 3:478–482.
10. Bernstein JE, Shalita AR: Topically applied erythromycin in inflammatory acne vulgaris. J Am Acad Dermatol 1980;2:318–321.
11. Jones EL, Crumley AF: Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol 1981;117:551–553.
12. Lesher JL, Chalker DK, Smith JG, et al: An evaluation of 2% erythromycin ointment in the topical therapy of acne vulgaris. J Am Acad Dermatol 1985;12:526–531.
13. Chalker DK, Shalita A, Smith JG, et al: A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983;9:933–936.
14. Feucht CL, Allen BS, Chalker DK, et al: Topical erythromycin with zinc in acne. J Am Acad Dermatol 1980;3:483–491.
15. Kuhlman DS, Callen JP: A comparison of clindamycin phosphate 1 percent topical lotion and placebo in the treatment of acne vulgaris. Cutis 1986;38:203–206.
16. Becker LE, Bergstresser PR, Whiting DA, et al: Topical clindamycin therapy for acne vulgaris. A cooperative clinical study. Arch Dermatol 1981;117:482–485.
17. Braathen LR: Topical clindamycin versus oral tetracycline and placebo in acne vulgaris. Scand J Infect Dis 1984;16(suppl 43):71–75.
18. Knutson DD, Swinyer LJ, Smoot WH: Meclocycline sulfosalicylate: Topical antibiotic agent for the treatment of acne vulgaris. Cutis 1981;27:203–210.
19. Leyden JJ, Shalita AR, Saatjian GD, et al: Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris. J Am Acad Dermatol 1987;16:822–827.
20. Thomas DR, Raimer S, Smith EB: Comparison of topical erythromycin 1.5 percent solution versus topical clindamycin phosphate 1.0 percent solution in the treatment of acne vulgaris. Cutis 1982;29:624–632.
21. Shalita AR, Smith EB, Bauer E: Topical erythromycin vs clindamycin therapy for acne. A multicenter, double-blind comparison. Arch Dermatol 1984;120:351–355.
22. Padilla RS, McCabe JM, Becker LE: Topical tetracycline hydrochloride vs clindamycin phosphate treatment of acne. A comparative study. Int J Dermatol 1981;20:445–448.
23. Rietschel RL, Duncan SH: Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol 1983;22:41–43.
24. Hjorth N, Schmidt H, Thomsen K, et al: Meclosorb, a new topical antibiotic agent in the treatment of acne vulgaris: A double-blind clinical study. Acta Derm Venereol 1984;64:354–357.
25. Stoughton RB, Cornell RC, Gange RW, et al: Double-blind comparison of topical 1 percent clindamycin phosphate (Cleocin T) and oral tetracycline 500 mg/day in the treatment of acne vulgaris. Cutis 1980;26:424–428.
26. Gratton D, Raymond GP, Guertin-Larochelle S, et al: Topical clindamycin versus systemic tetracycline in the treatment of acne. J Am Acad Dermatol 1982;7:50–53.
27. Rapaport M, Puhvel SM, Reisner RM: Evaluation of topical erythromycin and oral tetracycline in acne vulgaris. Cutis 1982;30:122–135.
28. Katsambas A, Towarky AA, Stratigos J: Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol 1987;116:387–391.
29. Parry MF, Rha C-K: Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 1986;122:583–584.
30. Milstore EB, McDonald AJ, Scholhamer CF: Pseudomembranous colitis after topical application of clindamycin. Arch Dermatol 1981;117:154–155.
31. Siegle RJ, Fekety R, Sarbone PD, et al: Effects of topical clindamycin on intestinal microflora in patients with acne. J Am Acad Dermatol 1986;15:180–185.
32. Barza M, Goldstein JA, Kane A, et al: Systemic absorption of clindamycin hydrochloride after topical application. J Am Acad Dermatol 1982;7:208–214.
33. Borglund E, Hagermark O, Nord CE: Impact of topical clindamycin and systemic tetracycline on the skin and colon microflora in patients with acne vulgaris. Scand J Infect Dis 1984;16(suppl 43):76–81.
34. Bernstein JE, Shalita AR: Effects of topical erythromycin on aerobic and anaerobic surface flora. Acta Derm Venereol 1980; 60:537–539.
35. Crawford WW, Crawford IP, Stoughton RB: Laboratory inductions and clinical occurrence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J Invest Dermatol 1979;72:187–190.
36. Eady EA, Holland KT, Cunliffe WJ: Topical antibiotics in acne therapy. J Am Acad Dermatol 1981;5:455–456.
37. Bleicher PA, Charles JH, Sober AJ: Topical metronidazole therapy for rosacea. Arch Dermatol 1987;123:609–614.
38. Nielsen PG: Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br J Dermatol 1983;108:327–332.
39. Veien NK, Christiansen JV, Hjorth N, et al: Topical metronidazole in the treatment of rosacea. Cutis 1986;38:209–210.
40. Nielsen PG: A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol 1983;109:63–65.
41. Nielsen PG: The relapse rate for rosacea after treatment with either oral tetracycline or metronidazole cream. Br J Dermatol 1983;109:122.
42. Mills OH, Kligman AM: Topically applied erythromycin in rosacea. Arch Dermatol 1976;112:553–554.
43. Clemmensen OJ: Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983;22:325–328.
44. Zaynoun ST, Matta MT, Uwayda MM, et al: Topical antibiotics in pyoderma. Br J Dermatol 1974;90:331–334.
45. Ruby RJ, Nelson JD: The influence of hexachlorophene scrubs on the response to placebo or penicillin therapy in impetigo. Pediatrics 1973;52:854–859.
46. Dillon HC: The treatment of streptococcal skin infections. J Pediatr 1970;76:676–684.
47. Burnett JW: The route of antibiotic administration in superficial impetigo. N Engl J Med 1963;268:72–75.
48. Hughes WT, Wan RT: Impetigo contagiosa: Etiology, complications and comparison of therapeutic effectiveness of erythromycin and antibiotic ointment. AJDC 1967;113:449–453.
49. Esterly NB, Markowitz M: The treatment of pyoderma in children. JAMA 1970;212:1667–1670.
50. Dillon HC: Topical and systemic therapy for pyodermas. Int J Dermatol 1980;19:443–451.
51. Baltimore RS: Treatment of impetigo: A review. Pediatr Infect Dis 1985;4:597–601.
52. Maddox JS, Ware JC, Dillon HC: The natural history of streptococcal skin infection: Prevention with topical antibiotics. J Am Acad Dermatol 1985;13:207–212.
53. Rojas R, Eels L, Eaglstein W, et al: The efficacy of Bactroban ointment and its vehicle in the treatment of impetigo: A double-blind comparative study, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 96–101.
54. Rojas R, Zaias N: The efficacy of Bactroban ointment in the treatment of impetigo as compared to its vehicle: A double-blind comparative study, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 150–154.
55. Eels LD, Mertz PM, Povianetti Y, et al: Topical antibiotic treatment of impetigo with mupirocin. Arch Dermatol 1986; 122:1273–1276.
56. Kennedy CTC, Watts JA, Speller DCE: Bacterial ointment in the treatment of impetigo: A controlled trial against neomycin, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 125–129.
57. Leyden JJ, Marples RR, Kligman AM: Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974;90:525–530.
58. Nilsson E, Henning C, Hjorleifsson ML: Density of the microflora in hand eczema before and after topical treatment with a potent corticosteroid. J Am Acad Dermatol 1986;15:192–197.
59. White MI, Noble WC: Consequences of colonization and infection by Staphylococcus aureus in atopic dermatitis. Clin Exp Dermatol 1986;11:34–40.
60. Hanifin JM, Rogge JL: Staphylococcal infections in patients with atopic dermatitis. Arch Dermatol 1977;113:1383–1386.
61. Wachs GN, Maibach HI: Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976;95:323–328.
62. Lloyd KM: The value of neomycin in topical corticosteroid preparations. South Med J 1969;62:94–96.
63. Leyden JJ, Kligman AM: The case for steroid-antibiotic combinations. Br J Dermatol 1977;96:179–187.
64. Ward A, Campoli-Richards DM: Mupirocin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986;32:425–444.
65. Leyden JJ: Double-blind vehicle-controlled studies of Bactroban ointment in secondary infections, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 183–189.
66. Orecchio RM, Mischler TW: A double-blind multiclinical trial of mupirocin topical and its vehicle in the treatment of bacterial skin infections. Curr Ther Res 1986;39:82–86.
67. Eaglstein WH: The efficacy and safety of Bactroban ointment and its vehicle in the treatment of secondary infected skin lesions in children, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 120–123.
68. Kreindler TG, Pekoe GM: A comparative study of Bactroban ointment and its vehicle in secondary infections of the skin, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 155–157.
69. Carney JM, Bickers DR: Vehicle-controlled study of Bactroban ointment in secondary skin infections, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 242–245.
70. Pekoe GM, Dobson RL: Vehicle-controlled study of Bactroban ointment in secondary infections, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 246–248.
71. Golitz LE, Beehler BJ: A comparative study of Bactroban ointment and its vehicle in secondary skin infections, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 249–252.
72. Rosenberg EW, Churchwell MA: Treatment of infected dermatitis with Bactroban ointment, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 257–259.
73. Whiting DA, Jacobson C, Menter MA: A comparative study of Bactroban ointment and its vehicle in patients 12 years and older with secondary skin infections, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 260–262.
74. Zone JJ, Weidner M: The treatment of secondary skin infections with Bactroban ointment: A vehicle-controlled study, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 263–265.
75. D'Alessandri RM, Gross J, Powers R: A comparative study of Bactroban ointment and its vehicle in the treatment of secondary infections of the skin, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 158–161.
76. DeBoer DC: A comparative study of Bactroban ointment and its vehicle in treating secondary infections of the skin, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 224–227.
77. Villiger JW, Robertson WD, Kanji K, et al: A comparison of the new topical antibiotic mupirocin (‘Bactroban’) with oral antibiotics in the treatment of skin infections in general practice. Curr Med Res Opin 1986;10:339–345.
78. Dux PH, Fields L, Pollock D: 2% topical mupirocin versus systemic erythromycin and cloxacillin in primary and secondary skin infections. Curr Ther Res 1986;40:933–940.
79. Williams JD, Waltho CA, Ayliffe GAJ, et al: Trials of five antibacterial creams in the control of nasal carriage of Staphylococcus aureus. Lancet 1967;2:390–392.
80. White A: The use of gentamicin as a nasal ointment. Am J Med Sci 1964;248:52–55.
81. Weinstein HJ: Control of nasal-staphylococcal-carrier states. N Engl J Med 1959;260:1308–1310.
82. Stokes EJ, Milne SE: Effect of Naseptin cream prophylaxis on staphylococcal infection in adult surgical wards and infant nurseries. J Hyg 1962;60:209–215.
83. Bryan CS, Wilson RS, Meade P, et al: Topical antibiotic ointments for staphylococcal nasal carriers: Survey of current practices and comparison of bacitracin and vancomycin ointments. Infect Control 1980;1:153–156.
84. White A, Smith J: Nasal reservoir as the source of extranasal staphylococci. Antimicrob Agents Chemother 1963;3:679–683.
85. Hunter DT, Baker CE: Control of staphylococcal carriers in three hospitals. Public Health Rep 1967;82:329–333.
86. Casewell MW, Hill RLR: Elimination of nasal carriage of Staphylococcus aureus with mupirocin (‘pseudomonic acid’): A controlled trial. J Antimicrob Chemother 1986;17:365–372.
87. Dacre JE, Emmerson AM, Jenner EA: Nasal carriage of gentamicin and methicillin resistant Staphylococcus aureus treated with topical pseudomonic acid. Lancet 1983;2:1036.
88. Casewell MW, Hill RLR, Duckworth GJ: The effect of mupirocin (pseudomonic acid) on the nasal carriage of Staphylococcus aureus, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 37–53.
89. Leyden JJ, James WD: Staphylococcus aureus infection as a complication of isotretinoin therapy. Arch Dermatol 1987;123:606–608.
90. Cochran RJ, Rosen T, Landers T: Topical treatment for erythrasma. Int J Dermatol 1981;20:562–564.
91. Pitcher DG, Noble WC, Seville RH: Treatment of erythrasma with miconazole. Clin Exp Dermatol 1979;4:453–456.
92. Kinney JP, Funk R: Topical treatment of gram-negative bacterial suprainfection in acne. Arch Dermatol 1980;116:597.
93. Wilson RG: Topical tetracycline in the treatment of perioral dermatitis. Arch Dermatol 1979;115:637.
94. Zaias N: Pitted and ringed keratolysis: A review and update. J Am Acad Dermatol 1982;7:787–791.
95. Nordstrom KM, McGinley KJ, Cappiello L, et al: Pitted keratolysis: The role of Micrococcus sedentarius. Arch Dermatol 1987;123:1320–1326.
96. White SW, Smith J: Trichomycosis pubis. Arch Dermatol 1979;115:444–445.
97. Irwin GR, Hart RJ, Martin CM: Pathogenesis and prevention of intravenous catheter infections. Yale J Biol Med 1973;46:85–93.
98. Zinner SH, Denny-Brown DC, Braun P, et al: Risk of infection with intravenous indwelling catheters: Effect of application of antibiotic ointment. J Infect Dis 1969;120:616–619.
99. Levy RS, Goldstein J, Pressman RS: Value of a topical antibiotic ointment in reducing bacterial colonization of percutaneous venous catheters. J Albert Einstein Med Center 1970;18:67–70.
100. Norden CW: Application of antibiotic ointment to the site of venous catheterization: A controlled trial. J Infect Dis 1969; 120:611–615.
101. Maki DG, Band JD: A comparative study of polyantibiotic and iodophor ointments in the prevention of vascular catheterrelated infection. Am J Med 1981;70:739–743.
102. Moran JM, Atwood RP, Rowe MI: A clinical and bacteriologic study of infections associated with venous cutdowns. N Engl J Med 1965;272:554–560.
103. Hirschmann JV: Controversies in antimicrobial prophylaxis. Chemioterapia 1987;6:202–207.
104. Fisher AA: Adverse reactions to topical clindamycin, erythromycin, and tetracycline. Cutis 1983;32:415–428.
105. Fisher AA: Adverse reactions to bacitracin, polymixin and gentamicin sulfate. Cutis 1983;32:510–512.
106. Held JL, Kalb RE, Ruszkowski AM, et al: Allergic contact dermatitis from bacitracin. J Am Acad Dermatol 1987;17:592–594.
107. Schechter JF, Wilkinson RD, DelCarpio J: Anaphylaxis following the use of bacitracin ointment: Report of a case and review of the literature. Arch Dermatol 1984;120:909–911.
108. Fraki JE, Peltonen L, Hopsu-Havu VK: Allergy to various components of topical preparations in stasis dermatitis and leg ulcer. Contact Dermatitis 1979;5:97–100.
109. Prystowsky DS, Allen AM, Smith RW, et al: Allergic contact hypersensitivity to nickel, neomycin, ethylene diamine, and benzocaine. Arch Dermatol 1979;115:959–962.
110. Leyden JJ, Kligman AM: Contact dermatitis to neomycin sulfate. JAMA 1979;242:1276–1278.
111. Noble WC: Choice of topical antibiotic: A microbiological view point. Clin Exp Dermatol 1981;6:503–507.
112. Quie PG, Collin M, Cardle JB: Neomycin-resistant staphylococci. Lancet 1960;2:124–126.
113. Lowbury EJL, Babb JR, Brown VI, et al: Neomycinresistant Staphylococcus aureus in a burns unit. J Hyg 1964; 62:221–228.
114. Alder VG, Gillespie WA: Influence of neomycin sprays on the spread of resistant staphylococci. Lancet 1967;2:1062–1063.
115. Rahman M, Noble WC, Cookson B: Mupirocin-resistant Staphylococcus aureus. Lancet 1987;2:387.
116. Baird D, Coia J: Mupirocin-resistant Staphyloccus aureus. Lancet 1987;2:387–388.
117. Kavi J, Andrews JM, Wise R: Mupirocin-resistant Staphylococcus aureus. Lancet 1987;2:1472.
118. Smith MD, Sanghrajka M, Lock S: Mupirocin-resistant Staphylococcus aureus. Lancet 1987;2:1472–1473.
119. Mack RM, Cantrell JR: Quantitative studies of the bacterial flora of open skin wounds. The effect of topical antibiotics. Ann Surg 1967;166:886–895.
120. Geronemus RG, Mertz PM, Eaglstein WH: Wound healing. The effects of topical antimicrobial agents. Arch Dermatol 1979;115:1311–1314.
121. Mertz PM, Dunlop BW, Eaglstein WH: The effects of Bactroban ointment on epidermal wound healing in partial thickness wounds, in Dobson R, Leyden JJ, Noble WC, et al (eds): Bactroban (Mupirocin). Princeton, NJ, Excerpta Medica, 1985, pp 211–215.